ISTH 2020 Congress

Platelet Disorders and von Willebrand Disease » Acquired Thrombocytopenias

Theme Navigation

ISTH 2020 Congress
- Platelet Disorders and von Willebrand Disease
  - Acquired Thrombocytopenias

Abstract Number: PB1365

A Long Term Survival Chronic DIC with ITP Treated with Low Dose Steroid

Y. Seki, O. Nagano

Abstract Number: PB1369

A Subpopulation of ITP Patients Resembling Glanzmann Thrombasthenia Phenotype Revealed by Flow Cytometry Analysis of Platelet Intracellular Signalling

A. Martyanov^1,2,3, D.S. Morozova⁴, S.S. Uzueva³, M.A. Sorokina³, D.V. Fedorova³, P.A. Zharkov³, M.A. Panteleev^2,3,5, A.N. Sveshnikova^2,3,5

Abstract Number: PB1335

Achieving Clinically Relevant Platelet Count Response Thresholds with Avatrombopag (AVA) in Immune Thrombocytopenia (ITP)

I. Altomare¹, M. Vredenburg², W. Tian², K. Aggarwal²

Abstract Number: PB1377

Antimicrobial Prophylaxis in Patients with Immune Thrombocytopenia Treated with Rituximab: A Retrospective Multicenter Analysis

S. Raso¹, M. Napolitano², G. Arrigo¹, F. Reale¹, P. Silimbiani³, A. Lucchesi⁴, A. Maggio⁵, G. Calvaruso⁵, U. Consoli⁶, M.F. Mansueto¹, S. Siragusa²

Abstract Number: PB1327

Antithyroid Treatment Improves Thrombocytopenia in a Young Patient with Graves´ Disease: A Case Report

V.V. Palmieri, G. Lassandro, A. Amoruso, V. Palladino, C. Pastore, P. Giordano

Abstract Number: PB1328

Apoptotic Markers May Help in Predicting the Disease Course of Pediatric Immune Thrombocytopenic Patients

S. Levy Mendelovich¹, S. Aviner², N. Sharon³, H. Miskin⁴, J. Yacobovich⁵, G. Kenet¹, H. Hauschner⁶, N. Rosenberg¹

Abstract Number: PB1366

Artificial Neural Network for Prediction of Hemorrhagic Severity in Patients with Immune Thrombocytopenia Purpura

L.P. de Carvalho¹, M.P. Colella², J.M. Annichino-Bizzacchi³, T.D. Martins⁴

Abstract Number: PB1331

Atorvastatin Restores the Imbalance of CD4⁺ T cells in Immune Thrombocytopenia via Ras/MEK/ERK and mTOR/PI3K/AKT Pathways

P. Xu¹, M. Xu², M. Hou²

Abstract Number: PB1315

Can we Predict the Clinical Course of Children with ITP by MPV? A Preliminary Study

Y. Lee¹, H. Yoon¹, S. Cho²

Abstract Number: PB1334

Can we Predict the Outcome of Splenectomy for Primary Immune Thrombocytopenia? Conclusion Based on Systematic Review and Meta-Analysis

M. Mitrovic^1,2, D. Antic^1,2, N. Milic³, M. Virijevic^1,2, Z. Pravdic¹, N. Sabljic¹, N. Pantic¹, N. Suvajdzic Vukovic^1,2

Abstract Number: PB1346

CD4⁺ T Cell Expression of IL-10 Compared to IL-17 is Lower in Patients with Immune Thrombocytopenia (ITP) Who Do Not Respond Clinically to High Dose Corticosteroid

M. Stimpson¹, P. Lait¹, L. Schewitz-Bowers¹, E. Williams¹, R. Lee^1,2, C. Bradbury^2,3

Abstract Number: PB1374

Characteristics and Outcome of Patients with Thrombocytopenia Secondary to Acute Cytomegalovirus Infection: Case Series and Literature Review

T. Shragai¹, E. Lebel², D. Deshet³, D. Varon^1,2, I. Avivi^1,4, I. Kirgner¹, N. Sarid¹

Abstract Number: PB1319

Characteristics of Patients with Cyclic Thrombocytopenia: An Observational Cohort Study

O. Steinbrecher¹, L. Eischer¹, H. Sinkovec², M. Mitrovic³, S. Eichinger¹, P.A. Kyrle¹

Abstract Number: PB1340

Clinical and Laboratory Factors Affecting Chronicity in Children Diagnosed with Immune Thrombocytopenia

Y. Ay¹, H. Sarbay²

Abstract Number: PB1347

Clinical Practise of SMOG System for Assessing Severity of Hemorrhagic Manifestations of Immume Thrombocytopenia (ITP) in Children

D. Sigunova, L. Zhukova, K. Papayan, A. Morozova

Abstract Number: PB1364

Comparison of Various Diagnostic Methods in Assessing Platelet Count in Patients with Immunotrombocytopenia

M. Witkowski¹, M. Witkowska², M. Tybura-Sawicka³, A. Majchrzak¹, J. Treliński³, K. Chojnowski³, T. Robak⁴, P. Smolewski²

Abstract Number: PB1378

Corticosteroid Reduction or Discontinuation after Initiation of Avatrombopag Treatment in Patients with Chronic Immune Thrombocytopenia (ITP)

M. Recht^1,2, A. Dixon³, K. Aggarwal³, M. Vredenburg³

Abstract Number: PB1330

Desmopressin for Procedures or Radiological Interventions (DRIVE): Participant Characteristics in a Placebo-Controlled Double-Blind, Randomised Feasibility Trial of Desmopressin in Thrombocytopenic Critically Ill Patients Prior to Procedures

M. Desborough¹, E. Laing², A. Griffiths³, A. Mora², R. Hodge², S. Martin², A. Shah⁴, P. Hutton⁵, T. Parke⁶, M. Wise⁷, M. Morgan⁷, S. McKechnie⁵, S. Stanworth^4,8, DRIVE Trial Investigators

Abstract Number: PB1336

Efficacy and Safety of Romiplostim in Children with Chronic and Persistent Immune Thrombocytopenic Purpura

M. Bordbar, M. Karimi

Abstract Number: PB1322

Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating Let-7b in Immune thrombocytopenia

Y. He, B. Zuo, C. Ruan

« View all themes from the ISTH 2020 Congress